Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 15/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | TCF7 | P36402 | 2/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | TCF4 | P15884 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14319182 | 0.94 | CLPP (0.54) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13773717 | 0.94 | CLPP (0.54) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14319520 | 0.93 | CLPP (0.45) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14309833 | 0.93 | CLPP (0.55) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14503854 | 0.93 | CLPP (0.55) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13773603 | 0.93 | CLPP (0.46) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13773665 | 0.93 | CLPP (0.46) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14319306 | 0.92 | CLPP (0.49) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL17572443 | 0.92 | CLPP (0.49) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14319181 | 0.92 | CLPP (0.57) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | CLPP 2188/4885CTNNB1 513/4885TCF7 1040/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | CLPP 2482/4885CTNNB1 101/4885TCF7 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.